Skip to content
Open access

Utility (or futility) of inpatient chemotherapy in patients with advanced solid organ cancers near end of life (FOCUS-EOL).

Oct 2026 · JCO Oncology Practice · 0 citations

Abstract

289 Background: Chemotherapy near the end of life carries limited clinical benefit. We evaluated outcomes of patients with solid organ malignancies who received inpatient cytotoxic chemotherapy at a tertiary cancer center. Methods: We performed a retrospective study of adults with solid organ malignancies who received inpatient cytotoxic chemotherapy at The Ohio State University Comprehensive Cancer Center between April 1, 2024 and March 30, 2025. Patients with hematologic malignancies, planned chemotherapy admissions, clinical trial participation, and those receiving non-cytotoxic systemic therapies were excluded. Outcomes included death during index admission and mortality at prespecified time points following chemotherapy. Continuous variables were summarized using means with standard deviations or medians. Overall survival was evaluated using Cox proportional hazards regression with adjustment for age, sex, metastatic disease status, treatment intent, and prior lines of therapy, with results reported as hazard ratios (HRs) and 95% confidence intervals (CIs). Results: Among 181 patients receiving inpatient chemotherapy, median age was 58 years (IQR 49–68), 54% were male, 85% had metastatic disease, and 87% received treatment with palliative intent. The most common malignancies were lung (27%), gastrointestinal (14%), breast (11%), and neuroendocrine cancers (9%), with symptom control being the leading indication for treatment (40%). 26 (14.4%) patients died during the index hospitalization. Mortality after inpatient chemotherapy was 7.7% at 7 days, 28.7% at 30 days, 43.6% at 60 days, 49.7% at 90 days, and 59.1% at 180 days, while 44% never received subsequent systemic therapy. ECOG 2 was more frequent among patients who died during hospitalization than survivors (52% vs 24%, p=0.025). In a predefined palliative cohort excluding small cell lung cancer, testicular cancer, sarcoma, and neuroendocrine malignancies (n=90), median survival was 57 days; 36% died within 30 days, 57% within 60 days, and 52% never received additional systemic treatment. Conclusions: Inpatient chemotherapy for advanced solid malignancies was associated with high early mortality and limited subsequent treatment, particularly in the palliative setting. Among patients receiving palliative chemotherapy excluding small cell lung cancer, testicular cancer, sarcoma, and neuroendocrine malignancies, median survival was only 57 days, with over half dying within 60 days, underscoring the need for careful patient selection and goals-of-care discussions.

Read PDF

Similar papers

Review Open access Oct 2026

Outcomes of inpatient chemotherapy following multidisciplinary review in patients with solid tumors at an academic cancer center.

Nearly one-third of patients undergoing multidisciplinary review for inpatient chemotherapy died within 30 days of request, highlighting the medical complexity of this population of patients.

Lawanya Singh, Tristan Lee, D. Hershman et al. · 0 citations
Oct 2026

Time Toxicity and End-of-Life Treatment of Metastatic Pancreatic Cancer.

Patients with metastatic PDAC spend roughly 1 in 5 days of survival engaged in health care interactions, creating substantial time toxicity-the time patients spend engaged with the health care system.

Patrick L. Quinn, M. Schaefer, Aslam M. Ejaz · 0 citations
Open access Oct 2026

Clinical drivers and early outcomes of inpatient chemotherapy in gastrointestinal oncology: A retrospective cohort study.

596 Background: Inpatient chemotherapy for gastrointestinal (GI) malignancies is used selectively for patients with urgent clinical needs or barriers to outpatient treatment, but indications, outcomes, and predictors of early mortality remain poorly defined. We characterized the clinical drivers and short-term...

A. Barabrah, M. Overman, Lian-Chun Xiao et al. · 0 citations
Open access Oct 2026

Functional status to predict acute care utilization among patients receiving systemic anticancer therapy in a QMENTUM diamond cancer center: A real-world cohort study.

The findings support the incorporation of PS assessment into routine oncology practice to identify patients who may benefit from targeted supportive care strategies and closer monitoring, supporting proactive care delivery within high-quality oncology programs.

Victória Santos Marques Pereira, Carolline Damas de Andrade Oliveira, Thays Andreza So Vale da Fonseca et al. · 0 citations
Open access Oct 2026

Contemporary Clinical Outcomes and Healthcare Utilization in Older Adults with Acute Myeloid Leukemia: Insights from a Single-Center Retrospective Cohort

Simple Summary Many older adults with acute myeloid leukemia (AML) cannot receive intensive treatment because of comorbidities or frailty. Newer, lower-intensity treatments have expanded options for these patients. In this retrospective analysis, we examined treatment patterns, survival, and healthcare utilization in p...

Tina Y. Zhang, Alex Y. Ge, Shyam A. Patel et al. · 0 citations
Open access Oct 2026

Treatment access and disparities in chemotherapy utilization among very elderly patients with metastatic NSCLC: A SEER-based quality of care analysis.

185 Background: Equitable access to systemic therapy is a measurable indicator of quality oncologic care, yet very elderly patients with metastatic non-small cell lung cancer (NSCLC) remain undertreated and underrepresented in clinical trials. The evolution of targeted therapies and immune checkpoint inhibitors...

Maryam Ali, S. Shah, Brian R. Theodore et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.